LZTFL1 rs10490770: What Your Genotype Means
The genetic variant rs10490770 is a single nucleotide polymorphism located within the 3p21.31 genomic region near the LZTFL1 gene. Originally inherited in part from archaic hominin lineages, this locus has been identified in large genome-wide association studies as a significant genetic marker for susceptibility to severe respiratory illness and downstream viral complications. Carrying the risk allele is associated with higher odds of severe lung involvement and related post-viral vascular pathology.
What each genotype means
Typical respiratory risk profile
You carry two copies of the common T allele at this locus, which has not been linked to heightened risk of critical respiratory complications. Research indicates that individuals with this baseline genotype experience typical population-level odds regarding viral-induced severe lung injury and downstream vascular complications. General preventative wellness measures and recommended standard immunizations remain the primary protective factors.
Carried by approximately 75% to 85% of individuals of European descent and is prevalent across many global populations.
Moderately increased respiratory vulnerability
You carry one copy of the C risk allele within the 3p21.31 locus near LZTFL1. Large-scale genome-wide association studies have linked this allele to an approximately twofold higher relative risk of severe viral respiratory failure and post-infection complications. However, genetic markers are only one component of outcome severity, and carrying this variant does not mean severe illness is inevitable.
Carried by approximately 15% to 25% of individuals of European ancestry and over 40% to 50% of people of South Asian ancestry.
Elevated respiratory risk profile
You carry two copies of the C risk allele associated with the 3p21.31 gene cluster containing LZTFL1. Observational research shows that homozygous carriers exhibit the highest statistical predisposition toward critical respiratory impairment and associated downstream inflammatory or vascular complications upon viral exposure. These findings describe population-level statistical risk rather than a definitive personal clinical prognosis.
Found in about 1% to 2% of people of European ancestry, but reaches frequencies above 10% to 15% in individuals of South Asian descent.
Genomic Location and the 3p21.31 Locus
The rs10490770 polymorphism resides on the short arm of human chromosome 3 at cytogenetic position 3p21.31. According to dbSNP and genomic coordinates, it is an intronic variant mapped adjacent to and within key regional genes, most notably leucine zipper transcription factor like 1 (LZTFL1) and solute carrier family 6 member 20 (SLC6A20). This specific stretch of chromosome 3 constitutes an extended linkage disequilibrium block—a tightly linked cluster of variants often inherited together. Evolutionary geneticists trace this entire 3p21.31 risk haplotype back to gene flow from archaic Neanderthal populations. Because many genetic markers in this segment correlate almost perfectly with one another, rs10490770 serves as a primary tag variant in population genetics for identifying carriers of this ancestral segment.
The Biological Role of LZTFL1
The LZTFL1 gene encodes leucine zipper transcription factor like 1, a cytoplasmic and ciliary protein expressed broadly across human tissues, with notable activity in pulmonary epithelial cells. Molecular studies indicate that LZTFL1 regulates epithelial-mesenchymal transition (EMT), an essential biological pathway by which stationary epithelial cells dynamically remodel and repair damaged tissue. When pulmonary cells undergo EMT in response to viral invasion, it acts as a localized defense and recovery mechanism. Research utilizing chromosome conformation capture and spatial transcriptomics demonstrates that regulatory variants linked to rs10490770 alter enhancer activity, driving an overexpression of LZTFL1. This overabundance can inhibit normal EMT signaling, impeding prompt cellular repair and potentially worsening pulmonary tissue damage during severe respiratory infections.
Research Findings and Clinical Evidence
During major global investigations led by the COVID-19 Host Genetics Initiative and individual hospital cohorts, the 3p21.31 locus emerged as the strongest common genetic signal linked to acute respiratory failure. In hospitalized individuals, carriers of the rs10490770 risk allele showed an approximate twofold increase in the risk of respiratory failure, alongside elevated odds of secondary complications including venous thromboembolism and acute hepatic injury. In some observational cohorts, risk allele carriers also showed statistical correlations with persistent post-acute post-viral symptoms. Despite these striking odds ratios in observational studies, the evidence is categorized as limited to moderate for direct predictive utility because genetics represents only one piece of the puzzle: clinical factors such as age, preexisting cardiometabolic conditions, and immune status remain far stronger determinants of illness severity.
Population Distribution and Ancestry Patterns
The frequency of rs10490770 varies considerably across global populations due to ancient evolutionary history and genetic drift. In individuals of European ancestry, the minor risk allele frequency generally ranges between 8% and 15%. By contrast, the risk allele is substantially more prevalent across South Asian populations, where carrier frequencies can exceed 50% to 60%. Meanwhile, the variant is observed at very low frequencies or is nearly absent in East Asian and African reference populations in large public repositories such as gnomAD. These pronounced geographical discrepancies help researchers explain some of the baseline disparities observed in respiratory illness outcomes across demographic groups, while highlighting that genetic risk estimates cannot be broadly extrapolated between different ancestral backgrounds without careful calibration.
What You Can and Cannot Conclude
Discovering your rs10490770 genotype provides an interesting window into ancestral genetics and statistical baseline biology, but it is not a clinical diagnosis or a definitive health forecast. Carrying one or two copies of the risk allele does not guarantee severe complications if exposed to respiratory pathogens, nor does possessing the baseline genotype provide complete immunity. General preventive measures—such as maintaining up-to-date immunizations, protecting cardiopulmonary health, and seeking prompt medical evaluation if you develop severe shortness of breath—remain the gold standard for personal health. Direct-to-consumer genetic data should never be used to alter medical treatments, prescribe medications, or replace professional healthcare evaluations. If you have concerns regarding chronic post-viral symptoms or cardiovascular wellness, discuss them directly with your physician.
How common is this variant?
The rs10490770 risk allele has a frequency of approximately 0.08 to 0.15 in European ancestry populations, but reaches over 50% to 60% in South Asian populations, while remaining rare among African and East Asian ancestries.
Frequently asked questions
Does having the rs10490770 risk allele guarantee I will get severe respiratory illness?
No. Genetic variants identified in genome-wide association studies merely indicate relative statistical predispositions across large populations. Severe respiratory outcomes are driven by a complex interplay of age, overall cardiovascular health, vaccination status, and viral exposure levels, meaning many people with the risk allele experience only mild illnesses.
Why is the rs10490770 variant described as Neanderthal DNA?
Evolutionary genomic research revealed that the 3p21.31 chromosomal segment containing rs10490770 entered the modern human gene pool via interbreeding with Neanderthals tens of thousands of years ago. As a result, the entire sequence block was preserved in varying frequencies across non-African modern human populations.
Can medication or lifestyle changes alter the risk associated with this variant?
You cannot change your underlying DNA sequence, but standard lifestyle and preventative medical practices significantly mitigate the clinical risks linked to viral respiratory illness. Staying current with recommended respiratory vaccinations, avoiding tobacco smoke, and managing baseline cardiovascular health remain the most effective ways to lower your risk of severe complications.
Is rs10490770 routinely tested in standard medical checkups?
No, testing for rs10490770 is not part of standard primary care or diagnostic screening. While it is frequently analyzed in academic research and reported in raw data files from direct-to-consumer genotyping services, clinical treatment guidelines do not currently alter patient care based on this specific SNP alone.
Sources & further reading
Educational information only, last refreshed 9/13/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs10490770?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29